|
|
Active Org.- |
|
Active Indication- |
|
Drug Highest PhaseSuspended |
First Approval Ctry. / Loc.- |
First Approval Date- |
A Phase 1, Open Label, First-in-human Study of TR1801-ADC, an Antibody Drug Conjugate (ADC), in Patients With Select Solid Tumors Expressing c-Met
First-in-human, Phase 1 study to assess safety, tolerability, and pharmacokinetics of TR1801-ADC in patients with select solid tumors that express c-Met.
100 Clinical Results associated with Open Innovation Partners Co., Ltd.
0 Patents (Medical) associated with Open Innovation Partners Co., Ltd.
100 Deals associated with Open Innovation Partners Co., Ltd.
100 Translational Medicine associated with Open Innovation Partners Co., Ltd.